Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 13:2:100015.
doi: 10.1016/j.cccb.2021.100015. eCollection 2021.

Potential recruitment into a clinical trial of vascular secondary prevention medications in cerebral small vessel disease, based on concomitant medication use

Edward Morrison  1 , Donald M Lyall  2 , Jill P Pell  2 , Daniel F Mackay  2 , Fergus N Doubal  3 , Joanna M Wardlaw  3 , Terence Quinn  4 , Stephen Makin  4   5
Affiliations

Potential recruitment into a clinical trial of vascular secondary prevention medications in cerebral small vessel disease, based on concomitant medication use

Edward Morrison et al. Cereb Circ Cogn Behav. .

Erratum in

Abstract

Background: Blood pressure-lowering medications, antiplatelet drugs and statins are often prescribed to asymptomatic patients with white matter hyperintensities (WMH). A clinical trial is needed, but potential trial participants would be excluded if they already had another indication to take the medication. It is likely that many patients with WMH would already have a recognised vascular-related indication for these drugs.We used data from the UK Biobank study to determine what proportion of people with WMH were not taking these drugs and would be potentially able to enter a clinical trial of antiplatelet drugs, statins, or BP-lowering medication.

Methods: We used the UK Biobank MRI sub-study of healthy volunteers aged 40-70 years as our cohort. We considered that WMH volumes in the top quartile (2.7-89 mls) were severe enough for a patient to be at risk of progression and be offered treatment. Such patients could also be included in a hypothetical clinical trial if there were no contraindications. Using the product licenses, we defined exclusion criteria for four hypothetical clinical trials of aspirin, clopidogrel, statins, and tight BP control. We then calculated what proportion of patients would still be eligible if these criteria were applied.

Results: 5794/23,179 patients had WMH in the top quartile. Of these, 4006/5794 69% (95% CI 68-70%) would be eligible for a trial of aspirin; with 81% (95% CI 80-82%) eligible for a trial of clopidogrel; 56% (95% CI 55-58%) of patients would be eligible to enter into a trial of a lower BP target, and 58% (95%CI 57-59%) would be able to enter a trial of a statin.

Conclusions: Over 80% of patients with WMH in the UK biobank would be eligible to enter a trial of an antiplatelet and just over half would be eligible to enter a trial of a statin or BP-lowering medication.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patients eligible for trials of (A) BP lowering and (B) statin medication. Participants may have been ineligible for multiple reasons.
Fig. 2
Fig. 2
Patients eligible for trials of (A) aspirin (B) clopidogrel medication. Participants may have been ineligible for multiple reasons.
See this image and copyright information in PMC

References

    1. Vermeer S.E., Longstreth W.T., Koudstaal P.J. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611–619. - PubMed
    1. Debette S., HS Markus. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666. - PMC - PubMed
    1. Bath P.M., Wardlaw J.M. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int. J. Stroke. 2015;10:469–478. - PMC - PubMed
    1. Wardlaw J., Bath P.M.W., Doubal F., et al. Protocol: the lacunar intervention trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease. Eur. Stroke J.; 0: 2396987320920110. - PMC - PubMed
    1. Makin S.D., Doubal F.N., Quinn T.J., et al. The effect of different combinations of vascular, dependency and cognitive endpoints on the sample size required to detect a treatment effect in trials of treatments to improve outcome after lacunar and non-lacunar ischaemic stroke. Eur. Stroke J. 2018;3:66–73. - PMC - PubMed

LinkOut - more resources